Breakthrough: How radiation helps the immune system kill cancer
Radiation therapy combined with the PD‑1 inhibitor pembrolizumab induces a systemic anti‑tumor immune response and improves clinical outcome in patients with immunologically cold non‑small cell lung cancer (NSCLC).
Radiation therapy combined with the PD‑1 inhibitor pembrolizumab induces a systemic anti‑tumor immune response and improves clinical outcome in patients with immunologically cold non‑small cell lung cancer (NSCLC).
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT